Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...

In addition to these features, the VIPRE Endpoint EDR+MDR package offers a fully managed incident response service led by a ...

The SELECT-MDS-1 trial showed no significant complete response rate improvement with tamibarotene plus azacitidine for ...

Syndax Pharmaceuticals has announced that its Phase II trial of revumenib achieved its primary endpoint in certain patients ...

"We offer MSPs a layer of value with secure, modern endpoint management, powered by both Microsoft Intune and Devicie and we ...

Almost half of adults and children with neurofibromatosis type 1 (NF1) responded to the investigational MEK inhibitor ...

High-profile vulns in NTLM, Windows Task Scheduler, Active Directory Certificate Services and Microsoft Exchange Server should be prioritised from November’s Patch Tuesday update Continue Reading ...

N4 Architecture talks about the design of its Birch Pavilion, which provides a space for work, relaxation and listening to ...

Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination ...

Ivanti Neurons is an all-in-one IT asset management and RMM tool perfect for large businesses and MSPs. Its excellent ...

Syros Pharmaceuticals announced that its phase 3 trial of tamibarotene in combination with azacitidine did not meet the primary endpoint for the treatment of myelodysplastic syndrome.

Ivanti is patching numerous security vulnerabilities in various products, some of which are critical. IT managers should take ...